Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS.

J Clin Oncol. 2005 Feb 1;23(4):792-9.

PMID:
15681523
2.

Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer.

Croom KF, Dhillon S.

Drugs. 2011 Nov 12;71(16):2213-29. doi: 10.2165/11207720-000000000-00000. Review.

PMID:
22035518
3.

Capecitabine: a review.

Walko CM, Lindley C.

Clin Ther. 2005 Jan;27(1):23-44. Review.

PMID:
15763604
4.

Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.

Leonard R, Hennessy BT, Blum JL, O'Shaughnessy J.

Clin Breast Cancer. 2011 Dec;11(6):349-56. doi: 10.1016/j.clbc.2011.06.005. Review.

PMID:
21856245
5.
6.

Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.

Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N.

Eur J Cancer. 2012 Mar;48(4):482-91. doi: 10.1016/j.ejca.2011.12.007. Epub 2012 Jan 16. Review.

PMID:
22257791
7.

Moving forward with capecitabine: a glimpse of the future.

Biganzoli L, Martin M, Twelves C.

Oncologist. 2002;7 Suppl 6:29-35. Review. Erratum in: Oncologist. 2003;8(1):127.

8.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D.

Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.

PMID:
20063120
9.

Current combination chemotherapy regimens for metastatic breast cancer.

Schwartz J.

Am J Health Syst Pharm. 2009 Dec 1;66(23 Suppl 6):S3-8. doi: 10.2146/ajhp090438. Review.

PMID:
19923317
11.

The role of angiogenesis inhibition in the treatment of breast cancer.

Sledge GW Jr, Rugo HS, Burstein HJ.

Clin Adv Hematol Oncol. 2006 Oct;4(10 Suppl 21):1-10; quiz 11-2. Review.

PMID:
17139244
12.

Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer.

Li L, Li J, Yang K, Tian J, Sun T, Jia W, Zhang P, Yi K.

Future Oncol. 2010 Feb;6(2):201-7. doi: 10.2217/fon.09.162. Review.

PMID:
20146579
13.
14.

Safety of bevacizumab in patients with metastatic breast cancer.

Hamilton EP, Blackwell KL.

Oncology. 2011;80(5-6):314-25. doi: 10.1159/000328757. Epub 2011 Jul 19. Review.

PMID:
21778772
15.

Evolution of bevacizumab-based therapy in the management of breast cancer.

Sachdev JC, Jahanzeb M.

Clin Breast Cancer. 2008 Oct;8(5):402-10. doi: 10.3816/CBC.2008.n.048. Review.

PMID:
18952553
16.

Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor.

Ignoffo RJ.

Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6. Review.

PMID:
15552623
17.

Single-agent vs combination therapy in advanced breast cancer: potential roles of capecitabine.

Hudis CA.

Oncology (Williston Park). 2002 Oct;16(10 Suppl 12):13-6. Review.

18.

Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.

Riera R, Soárez PC, Puga ME, Ferraz MB.

Sao Paulo Med J. 2009 Sep;127(5):295-301. Review.

19.

Recent translational research: antiangiogenic therapy for breast cancer - where do we stand?

Miller KD.

Breast Cancer Res. 2004;6(3):128-32. Epub 2004 Mar 18. Review.

20.

Capecitabine.

Dooley M, Goa KL.

Drugs. 1999 Jul;58(1):69-76; discussion 77-8. Review.

PMID:
10439930

Supplemental Content

Support Center